Efficacy, Tolerability, and Safety of Low-Volume Bowel Preparations for Patients with Inflammatory Bowel Diseases: The French Multicentre CLEAN Study
Authors:
- 13 February 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 13 (9) , 1121-1130
Abstract
Background: Standard high-volume polyethylene glycol [PEG] bowel preparations [PEG-4L] are recommended for patients with inflammatory bowel disease [IBD] undergoing colonoscopy. However, low-volume preparations [≤2 L of active volume] are often used in clinical practice. The aim of this study was to evaluate the efficacy, tolerability, and safety of the various bowel preparations for patients with IBD, including low-volume preparations. Methods: We conducted a French prospective multicentre observational study over a period of 1 month. Patients aged 18–75 years with IBD with an indication of colonoscopy independent of the study were enrolled. The choice of the preparation was left to the investigators, as per their usual protocol. The patients’ characteristics, disease, and colonoscopy characteristics were recorded, and they were given self-reported questionnaires. Results: Twenty-five public and private hospitals enrolled 278 patients. Among them, 46 had a disease flare and 41 had bowel stenoses. Bowel preparations for colonoscopy were as follows: 42% received PEG-2L, 29% received sodium picosulfate [Pico], 15% received PEG-4L, and 14% had other preparations. The preparation did not reach the Boston’s score efficacy outcome in the PEG-4L group in 51.2% of the patients [p = 0.0011]. The preparation intake was complete for 59.5% in the PEG-4L group, compared with 82.9% in the PEG-2L group and 93.8% in the Pico group [p < 0.0001]. Tolerability, as assessed by the patients’ VAS, was significantly better for both Pico and PEG-2L compared with PEG-4L, and better for Pico compared with PEG-2L [p = 0.008; p = 0.0003]. In multivariate analyses, low-volume preparations were independent factors of efficacy and tolerability. Adverse events occurred in 4.3% of the patients. Conclusions: Preparations with PEG-2L and Pico were equally safe, with better efficacy and tolerability outcomes compared with PEG-4L preparations. The best efficacy/tolerance/safety profile was achieved with the Pico preparation.Keywords
Funding Information
- Merck Sharp and Dohme United Kingdom
This publication has 32 references indexed in Scilit:
- Bowel cleansing for colonoscopy: prospective randomized assessment of efficacy and of induced mucosal abnormality with three preparation agentsEndoscopy, 2011
- Impact of Low-Residue Diet on Bowel Preparation for ColonoscopyDiseases of the Colon & Rectum, 2011
- Comprehensive validation of the Boston Bowel Preparation ScaleGastrointestinal Endoscopy, 2010
- Meta‐analysis: randomized controlled trials of 4‐L polyethylene glycol and sodium phosphate solution as bowel preparation for colonoscopyAlimentary Pharmacology & Therapeutics, 2010
- Evolving paradigms in the pathogenesis of IBDJournal of Gastroenterology, 2009
- Duration of the interval between the completion of bowel preparation and the start of colonoscopy predicts bowel-preparation qualityGastrointestinal Endoscopy, 2009
- The Boston bowel preparation scale: a valid and reliable instrument for colonoscopy-oriented researchGastrointestinal Endoscopy, 2009
- Systematic review: oral bowel preparation for colonoscopyAlimentary Pharmacology & Therapeutics, 2006
- Which is the optimal bowel preparation for colonoscopy – a meta‐analysisColorectal Disease, 2006
- Colonic mucosal abnormalities associated with oral sodium phosphate solutionGastrointestinal Endoscopy, 1996